Breakout Ventures closes $114M Fund III dedicated exclusively to early-stage neurotech
Summary
Breakout Ventures closed $114M for Fund III, their dedicated early-stage neurotech fund targeting 20-25 investments across BCIs, neuromodulation, AI brain diagnostics, and digital mental health. As one of the few VC funds exclusively focused on neurotech, Breakout brings domain expertise in FDA pathways, clinical development timelines, and neurotech commercial models that generalist VCs lack. Fund III LP base includes university endowments, family offices, and institutional health system investors.
Why it matters
A $114M dedicated neurotech early-stage fund is the infrastructure signal that the sector has matured enough to support specialist capital at scale. Breakout Fund III will fund the companies in the 2025-2027 cohort that will define the neurotech landscape in the 2030s — seeding the next generation of companies that follow Neuralink's and Synchron's regulatory trail.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial